Literature DB >> 21659402

Latest developments in the treatment of melanoma: 'a penicillin moment for cancer'?

Spyros Retsas1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21659402      PMCID： PMC3110965          DOI： 10.1258/jrsm.2011.100405

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  22 in total

1.  Treatment at random: the ultimate science or the betrayal of Hippocrates?

Authors:  Spyros Retsas
Journal:  J Clin Oncol       Date:  2004-12-15       Impact factor: 44.544

2.  Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma.

Authors:  Ravi D Rao; Shernan G Holtan; James N Ingle; Gary A Croghan; Lisa A Kottschade; Edward T Creagan; Judith S Kaur; Henry C Pitot; Svetomir N Markovic
Journal:  Cancer       Date:  2006-01-15       Impact factor: 6.860

3.  Resistance to BRAF inhibition in melanomas.

Authors:  David B Solit; Neal Rosen
Journal:  N Engl J Med       Date:  2011-02-24       Impact factor: 91.245

4.  Taxol and vinorelbine: a new active combination for disseminated malignant melanoma.

Authors:  S Retsas; A Mohith; H Mackenzie
Journal:  Anticancer Drugs       Date:  1996-02       Impact factor: 2.248

5.  Central nervous system involvement in malignant melanoma.

Authors:  S Retsas; A R Gershuny
Journal:  Cancer       Date:  1988-05-01       Impact factor: 6.860

6.  Identification of a new HLA-A(*)0201-restricted T-cell epitope from the tyrosinase-related protein 2 (TRP2) melanoma antigen.

Authors:  Y Sun; M Song; S Stevanović; C Jankowiak; A Paschen; H G Rammensee; D Schadendorf
Journal:  Int J Cancer       Date:  2000-08-01       Impact factor: 7.396

7.  A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III).

Authors:  C M Balch; S J Soong; T M Murad; J W Smith; W A Maddox; J R Durant
Journal:  J Clin Oncol       Date:  1983-02       Impact factor: 44.544

8.  Clinical and histologic involvement of regional lymph nodes in malignant melanoma. Adjuvant vindesine improves survival.

Authors:  S Retsas; M Quigley; D Pectasides; K Macrae; K Henry
Journal:  Cancer       Date:  1994-04-15       Impact factor: 6.860

9.  Prognostic factors in 1,521 melanoma patients with distant metastases.

Authors:  A Barth; L A Wanek; D L Morton
Journal:  J Am Coll Surg       Date:  1995-09       Impact factor: 6.113

10.  Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.

Authors:  T Eisen; T Ahmad; K T Flaherty; M Gore; S Kaye; R Marais; I Gibbens; S Hackett; M James; L M Schuchter; K L Nathanson; C Xia; R Simantov; B Schwartz; M Poulin-Costello; P J O'Dwyer; M J Ratain
Journal:  Br J Cancer       Date:  2006-08-01       Impact factor: 7.640
View more
  3 in total

1.  Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use.

Authors:  Chris Fellner
Journal:  P T       Date:  2012-09

2.  Specifically targeting ERK1 or ERK2 kills melanoma cells.

Authors:  Jianzhong Qin; Hong Xin; Brian J Nickoloff
Journal:  J Transl Med       Date:  2012-01-25       Impact factor: 5.531

Review 3.  Emerging options for the treatment of melanoma - focus on ipilimumab.

Authors:  Claire Roddie; Karl S Peggs
Journal:  Immunotargets Ther       Date:  2014-03-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.